Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 9/20 | 0.45 |
| ▸ | TP53 | P04637 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23127282 | 1.00 | MAOB (0.47) | MAOBMAPTTP53NPC1RAB9A | |
| SCHEMBL23127280 | 1.00 | MAOB (0.47) | MAOBMAPTTP53NPC1RAB9A | |
| SCHEMBL19324899 | 0.95 | LMNA (0.49) | MAOBMAPTTP53NPC1RAB9A | |
| SCHEMBL19319530 | 0.95 | LMNA (0.49) | MAOBMAPTTP53NPC1RAB9A | |
| SCHEMBL19351642 | 0.95 | LMNA (0.49) | MAOBMAPTTP53NPC1RAB9A | |
| SCHEMBL20779501 | 0.95 | MAOB (0.47) | MAOBMAPTTP53NPC1RAB9A | |
| SCHEMBL23127122 | 0.94 | MAPT (0.52) | MAPTTP53NPC1RAB9AKCNQ3 | |
| SCHEMBL23127120 | 0.94 | MAPT (0.52) | MAPTTP53NPC1RAB9AKCNQ3 | |
| SCHEMBL25945989 | 0.94 | MAPT (0.52) | MAPTTP53NPC1RAB9AKCNQ3 | |
| SCHEMBL25949518 | 0.94 | MAPT (0.52) | MAPTTP53NPC1RAB9AKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | MAOB 675/4885MAPT 4660/4885TP53 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.